Mark Muthiah
Overview
Explore the profile of Mark Muthiah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
892
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tham E, Tan D, Danpanichkul P, Ng C, Syn N, Koh B, et al.
Liver Int
. 2025 Feb;
45(3):e70001.
PMID: 39927433
Background And Aim: The burden of cirrhosis and other chronic liver diseases has changed in recent years due to shifts in the contributing aetiologies. We estimated the burden of cirrhosis...
2.
Kong G, Koh J, Chia J, Neo B, Chen Y, Cao G, et al.
Cardiovasc Diabetol
. 2025 Feb;
24(1):59.
PMID: 39920748
Background: Emerging evidence has demonstrated the unfavourable cardiovascular risk of individuals with lean type 2 diabetes mellitus (T2DM). Our study aims to investigate the prognostic value of lean T2DM in...
3.
Faulkner C, Aboona M, Surendra L, Rangan P, Ng C, Huang D, et al.
Clin Gastroenterol Hepatol
. 2024 Dec;
PMID: 39675403
Background & Aims: Significant health disparities exist in metabolic dysfunction-associated steatotic liver disease (MASLD), driven by social determinants of health (SDOH). Few studies have explored neighborhood-level SDOH in MASLD. Methods:...
4.
Koh J, Mohamed A, Kong G, Wong E, Chen Y, Anand V, et al.
Diabetes Obes Metab
. 2024 Nov;
27(2):683-696.
PMID: 39529446
Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity increases risk of cardiovascular disease. This cohort study examines the prognostic value of MASLD, across body weight categories, in a secondary...
5.
Muralidharan S, Lee J, Lim Y, Muthiah M, Tan E, Demicioglu D, et al.
Metabolism
. 2024 Nov;
162:156063.
PMID: 39522592
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a spectrum of pathologies ranging from simple steatosis to steatohepatitis, fibrosis and cirrhosis. Patients with metabolic associated steatohepatitis (MASH) with...
6.
Tan D, Tamaki N, Kim B, Wijarnpreecha K, Aboona M, Faulkner C, et al.
Aliment Pharmacol Ther
. 2024 Oct;
61(2):278-285.
PMID: 39462858
Background: Major society guidelines recommend the fibrosis-4 index (FIB-4) as the initial step to risk stratifying people with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to evaluate the proportion...
7.
Tham E, Lim R, Koh B, Tan D, Ng C, Law M, et al.
Clin Gastroenterol Hepatol
. 2024 Oct;
PMID: 39461458
Background And Aims: Chronic liver disease is a known risk factor for cholangiocarcinoma (CCA), but the proportion of people with CCA who have concurrent chronic liver disease is unclear. We...
8.
Chong B, Jayabaskaran J, Jauhari S, Chan S, Goh R, Kueh M, et al.
Eur J Prev Cardiol
. 2024 Sep;
PMID: 39270739
Aims: The prediction of future trends in cardiovascular disease (CVD) mortality and their risk factors can assist policy-makers in healthcare planning. This study aims to project geospatial trends in CVDs...
9.
Goh R, Chong B, Jayabaskaran J, Jauhari S, Chan S, Kueh M, et al.
Lancet Reg Health West Pac
. 2024 Aug;
49:101138.
PMID: 39100533
Background: Given the rapidly growing burden of cardiovascular disease (CVD) in Asia, this study forecasts the CVD burden and associated risk factors in Asia from 2025 to 2050. Methods: Data...
10.
Koh B, Xiao J, Ng C, Law M, Gunalan S, Danpanichkul P, et al.
Hepatology
. 2024 Jul;
PMID: 39028914
Background And Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of liver disease. Dynamic changes in MRI proton-density-fat fraction (PDFF) are associated with MASH resolution. We aimed to determine...